Andrew Lo Biography and Net Worth

Director of BridgeBio Pharma

Andrew W. Lo, Ph.D. has served as a member of our Board of Directors since June 2020. Dr. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of the MIT Laboratory for Financial Engineering, a principal investigator at the MIT Computer Science and Artificial Intelligence Laboratory, and an affiliated faculty member of the MIT Department of Electrical Engineering and Computer Science, and has served as a professor at the MIT Sloan School of Management and MIT Department of Electrical Engineering and Computer Science since 1988. He is also an external faculty member of the Santa Fe Institute and a research associate of the National Bureau of Economic Research. Dr. Lo currently serves on the board of directors of clinical-stage and preclinical biopharmaceutical companies, including AbCellera Biologics Inc. (Nasdaq: ABCL) since December 2021, Roivant Sciences, Inc. (Nasdaq: ROIV) since July 2016 and Atomwise Inc. since June 2021. Dr. Lo holds a B.A. in Economics from Yale University and a Ph.D. in Economics from Harvard University. Dr. Lo’s qualifications to serve on our Board of Directors include his extensive experience as a professor and a leader at two premier educational institutions.

What is Andrew Lo's net worth?: The estimated net worth of Andrew Lo is at least $3.72 million as of November 18th, 2025. Dr. Lo owns 50,583 shares of BridgeBio Pharma stock worth more than $3,724,932 as of December 8th. This net worth approximation does not reflect any other investments that Dr. Lo may own. Learn More about Andrew Lo's net worth.
How do I contact Andrew Lo?: The corporate mailing address for Dr. Lo and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Andrew Lo's contact information.
Has Andrew Lo been buying or selling shares of BridgeBio Pharma?: During the last ninety days, Andrew Lo has sold $6,319,685.33 of BridgeBio Pharma stock. Most recently, Andrew Lo sold 55,000 shares of the business's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.69, for a transaction totalling $3,612,950.00. Following the completion of the sale, the director now directly owns 50,583 shares of the company's stock, valued at $3,322,797.27. Learn More on Andrew Lo's trading history.
Who are BridgeBio Pharma's active insiders?: BridgeBio Pharma's insider roster includes Douglas Dachille (Director), Ronald Daniels (Director), Andrea Ellis (Director), Neil Kumar (CEO), Andrew Lo (Director), Frank McCormick (Director), Richard Scheller (Insider), Randal Scott (Director), Brian Stephenson (CFO), and Hannah Valantine (Director). Learn More on BridgeBio Pharma's active insiders.
Are insiders buying or selling shares of BridgeBio Pharma?: In the last year, insiders at the sold shares 44 times. They sold a total of 20,694,037 shares worth more than $763,116,802.77. The most recent insider tranaction occured on November, 20th when CEO Neil Kumar sold 26,156 shares worth more than $1,722,111.04. Insiders at BridgeBio Pharma own 18.2% of the company. Learn More about insider trades at BridgeBio Pharma.
Information on this page was last updated on 11/20/2025.

Andrew Lo Insider Trading History at BridgeBio Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/18/2025	Sell	55,000	$65.69	$3,612,950.00	50,583
11/17/2025	Sell	40,599	$66.67	$2,706,735.33	14,089
5/2/2025	Sell	100,000	$38.50	$3,850,000.00	105,583

Andrew Lo Buying and Selling Activity at BridgeBio Pharma

BridgeBio Pharma Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Today's Range

Now: $73.64

$72.38

$74.86

50 Day Range

MA: $62.01

$51.94

$74.76

2 Week Range

Now: $73.64

$25.34

$75.04

Volume

1,938,807 shs

Average Volume

1,996,766 shs

Market Capitalization

$14.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.25